Beyond the Horizon: The Next-Generation Science and Benefits of Retatrutide
The triple-G molecule: one weekly injection acting at GLP-1, GIP and glucagon at once. What the trials reported — 28.3% at 80 weeks, 30.3% at 104, HbA1c, liver fat, blood pressure and a 75.8% cut in joint pain — with the trial named against each figure.